Noscapine inhibits tumor growth in TMZ-resistant gliomas

Cancer Letters

Volumn 312, Issue 2, 2011, Pages 245-252

  Jhaveri, Niyati ^a   Cho, Heeyeon ^a   Torres, Shering ^a   Wang, Weijun ^a   Schönthal, Axel H ^a   Petasis, Nicos A ^b   Louie, Stan G ^b   Hofman, Florence M ^a   Chen, Thomas C ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Dept of Neurosurgery ^*  (United States)

Author keywords

Brain tumors; Glioma; Invasion; Noscapine; Temozolomide resistance

Indexed keywords

NOSCAPINE; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CELL; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NOSCAPINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 80054006821     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.015     Document Type: Article

References (29)

1. Deorah S., Lynch C.F., Sibenaller Z.A., Ryken T.C. Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg. Focus 2006, 20(4):E1.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 2005, 352(10):987-996.
3. Stupp R., Hegi M.E., van den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., Cairncross J.G. Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 2006, 11(2):165-180.
4. Dehdashti A.R., Hegi M.E., Regli L., Pica A., Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg. Focus 2006, 20(4):E6.
5. Holland E.C. Glioblastoma multiforme: the terminator. Proc. Natl Acad. Sci. USA 2000, 97(12):6242-6244.
6. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., Pica A., Maillard I., Maeder P., Meuli R., Janzer R., Pizzolato G., Miralbell R., Porchet F., Regli L., de Tribolet N., Mirimanoff R.O., Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002, 20(5):1375-1382.
7. Lu C., Shervington A. Chemoresistance in gliomas. Mol. Cell. Biochem. 2008, 312:71-80.
8. Segal M.S., Goldstein M.M., Attinger E.O. The use of noscapine (narcotine) as an antitussive agent. Dis. Chest 1957, 32(3):305-309.
9. H. Eagle, G. Foley, Report to CCNSC Screening Section, 1958.
10. Lettre H. Synergists and antagonists of mitotic poisons. Ann. N. Y. Acad. Sci. 1954, 58:1264.
11. Ye K., Ke Y., Keshava N., Shanks J., Kapp J.A., Tekmal R.R., Petros J., Joshi H.C. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl Acad. Sci. USA 1998, 95(4):1601-1606.
12. Zhou J., Panda D., Landen J.W., Wilson L., Joshi H.C. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J. Biol. Chem. 2002, 277(19):17200-17208.
13. Landen J.W., Lang R., McMahon S.J., Rusan N.M., Yvon A.M., Adams A.W., Sorcinelli M.D., Campbell R., Bonaccorsi P., Ansel J.C., Archer D.R., Wadsworth P., Armstrong C.A., Joshi H.C. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 2002, 62(14):4109-4114.
14. Zhou J., Gupta K., Yao J., Ye K., Panda D., Giannakakou P., Joshi H.C. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J. Biol. Chem. 2002, 277(42):39777-39785.
15. Jackson T., Chougule M.B., Ichite N., Patlolla R.R., Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother. Pharmacol. 2008, 63(1):117-126.
16. Heidari N., Goliaei B., Moghaddam P.R., Rahbar-Roshandel N., Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 2007, 18(10):1139-1147.
17. Aneja R., Ghaleb A.M., Zhou J., Yang V.W., Joshi H.C. P53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 2007, 67(8):3862-3870.
18. Newcomb E.W., Lukyanov Y., Smirnova I., Schnee T., Zagzag D. Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs 2008, 19(6):553-563.
19. Ke Y., Ye K., Grossniklaus H.E., Archer D.R., Joshi H.C., Kapp J.A. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol. Immunother. 2000, 49(4-5):217-225.
20. Barken I., Geller J., Rogosnitzky M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res. 2008, 28(6A):3701-3704.
21. Landen J.W., Hau V., Wang M., Davis T., Ciliax B., Wainer B.H., Van Meir E.G., Glass J.D., Joshi H.C., Archer D.R. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004, 10(15):5187-5201.
22. Newcomb E.W., Lukyanov Y., Schnee T., Ali M.A., Lan L., Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1alpha expression and angiogenesis in vitro: a novel function for an old drug. Int. J. Oncol. 2006, 28(5):1121-1130.
23. Virrey J.J., Golden E.B., Sivakumar W., Wang W., Pen L., Schönthal A.H., Hofman F.M., Chen T.C. Glioma-associated endothelial cells are chemoresistant to temozolomide. J. Neurooncol. 2009, 95(1):13-22.
24. Charalambous C., Pen L.B., Su Y.S., Milan J., Chen T.C., Hofman F.M. Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res. 2005, 65(22):10347-10354.
25. Franceschi E., Tosoni A., Bartolini S., Mazzocchi V., Fioravanti A., Brandes A.A. Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev. Anticancer Ther. 2009, 9(5):613-619.
26. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nuñez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 2009, 16(1):3-11.
27. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 1971, 285(21):1182-1186.
28. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974.
29. Newcomb E.W., Lukyanov Y., Alonso-Basanta M., Esencay M., Smirnova I., Schnee T., Shao Y., Devitt M.L., Zagzag D., McBride W., Formenti S.C. Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71(5):1477-1484.